

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-36 (canceled)

Claim 37 (previously presented): A method for reducing tissue factor levels to treat tumors exhibiting tissue factor expression, comprising administering to a mammal having the tumor a therapeutically effective amount of an antibody that comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO:4, or fragment thereof that binds native human tissue factor to form a complex, whereby Factor X binding to the complex is inhibited and Factor VII or VIIa binding to tissue factor is not inhibited.

Claim 38 (canceled)

Claim 39 (previously presented): The method of claim 37, wherein the antibody or fragment has the binding specificity for native human tissue factor about equal to or greater than H36.D2.B7 deposited as ATCC HB12255.

Claim 40 (canceled)

Claim 41 (previously presented): The method of claim 37, wherein the antibody is H36.D2.B7 deposited as ATCC HB-12255.

Claim 42 (previously presented): The method of claim 37, wherein the antibody is a monoclonal antibody.

Claim 43 (previously presented): The method of claim 37, wherein the antibody is a chimeric antibody.

Claim 44 (previously presented): The method of claim 43, wherein the chimeric antibody further comprises a constant region of human origin.

Claim 45 (previously presented): The method of claim 37, wherein the antibody is a humanized antibody and comprises at least one hypervariable regions of non-human origin.

Claim 46 (previously presented): The method of claim 37, wherein the antibody is a single chain antibody.

Claims 47-53 (canceled)

Claim 54 (previously presented): The method of claim 37, wherein the fragment is a Fab, F(v), Fab', or F(ab')₂ fragment.

Claim 55 (previously presented): The method of claim 37, wherein the Factor X binding to the complex is inhibited by at least 80 percent in a standard in vitro binding assay.

Claims 56-57 (canceled)

Claim 58 (previously presented): The method of claim 37, wherein administration of the antibody increases the clotting time by at least 90 percent according to a prothrombin time (PT) assay.

Claims 59-64 (canceled)

Claim 65 (previously presented): The method of claim 43, wherein the chimeric antibody comprises a mouse variable region.

Claims 66-82 (canceled)

Claim 83 (currently amended): A method for reducing tissue factor (TF) levels to treat a tumor[[s]] exhibiting tissue factor expression, comprising administering to a human having the tumor[[s]] a therapeutically effective amount of an anti-TF antibody that comprises six hypervariable regions which comprise sequences of SEQ ID NOs: 5-10 or a chimeric antibody of such anti-TF antibody.

Claim 84 (previously presented): The method of claim 83, wherein the antibody binds native human tissue factor to form a complex, whereby Factor X binding to the complex is inhibited and Factor VII or VIIa binding to tissue factor is not inhibited.

Claim 85 (previously presented): The method of claim 83, wherein the antibody is a chimeric antibody.

Claim 86 (previously presented): The method of claim 85, wherein the chimeric antibody comprises a mouse variable region.

Claim 87 (currently amended): The method of claim 83, wherein the antibody is a chimeric antibody and ~~has at least 90% amino acid sequence identity to~~ comprises the sequences of SEQ ID NO: 2 and SEQ ID NO: 4.

Claim 88 (canceled)

Claim 89 (previously presented): The method of claim 83, wherein the antibody comprises a constant region of human origin.

Claim 90 (previously presented): The method of claim 83, wherein the antibody is an immunologically active antibody fragment.

Claim 91 (previously presented): The method of claim 83, wherein the antibody is a Fab, F(v), Fab', or F(ab')₂.

Claim 92 (previously presented): The method of claim 83, wherein the antibody is a single chain antibody.

Claim 93 (canceled)

Claim 94 (previously presented): The method of claim 83, wherein the six hypervariable regions are encoded by the nucleic acid sequences of SEQ ID NOs: 11-16.

Claim 95 (previously presented): The method of claim 83, wherein the Factor X binding to the complex is inhibited by at least 80 percent in a standard in vitro binding assay.

Claim 96 (previously presented): The method of claim 83, wherein administration of the antibody increases the clotting time by at least 90 percent according to a prothrombin time (PT) assay.